These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 24800502)
1. [Biological markers for early diagnosis of Alzheimer's disease]. Taniguchi M; Urakami K Rinsho Byori; 2014 Mar; 62(3):261-6. PubMed ID: 24800502 [TBL] [Abstract][Full Text] [Related]
3. [The role of CSF markers in the early diagnosis of Alzheimer's disease]. Vos SJ; Visser PJ; Verhey FR Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322 [TBL] [Abstract][Full Text] [Related]
4. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Alzheimer's disease in body fluids. Zheng Y; He J; Hong T Sci China Life Sci; 2010 Apr; 53(4):490-6. PubMed ID: 20596916 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877 [TBL] [Abstract][Full Text] [Related]
7. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Alzheimer's disease: the present and the future. Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316 [TBL] [Abstract][Full Text] [Related]
9. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781 [TBL] [Abstract][Full Text] [Related]
10. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482 [TBL] [Abstract][Full Text] [Related]
11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174 [TBL] [Abstract][Full Text] [Related]
15. Preclinical AD predicts decline in memory and executive functions in subjective complaints. van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134 [TBL] [Abstract][Full Text] [Related]
16. Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment. Riepe MW; Karl J; Tumani H; von Arnim CA Dement Geriatr Cogn Disord; 2010; 30(2):93-100. PubMed ID: 20720423 [TBL] [Abstract][Full Text] [Related]
17. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Engelborghs S; Le Bastard N J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896 [TBL] [Abstract][Full Text] [Related]
18. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010 [TBL] [Abstract][Full Text] [Related]
19. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742 [TBL] [Abstract][Full Text] [Related]
20. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]